Featured News
Finland Site Moves to New Facility
Expanded capabilities for drug discovery
To help researchers accelerate drug discovery, our Kuopio, Finland facility has expanded its translational pharmacology capabilities. With increased research capacity and integrated advanced imaging and biomarker analysis, we provide the precise insights needed to drive progress in neuroscience, oncology, and metabolic disease research.
The Kuopio site focuses on non-GLP pharmacology studies, with extensive expertise in small animal imaging (MRI, PET, and functional ultrasound), behavior and motor testing, and biomarker analysis. The move to a brand-new, purpose-built facility expands total research space by 40%, providing enhanced resources including:
- Dedicated vivarium and surgical suites
- Small animal imaging core facilities
- Behavioral and physiological testing facilities
- BSL2 biosecurity rooms
- Wet labs for biomarker analysis
- Collaborative workspaces for interdisciplinary research
Historically focused on neuroscience and rare disease, the expansion of these facilities also enables support for other therapeutic areas including dedicated resources for oncology drug discovery, and further support for growing drug discovery in cardiovascular and metabolic diseases.
Recognition of the huge unmet need across the spectrum of neurological disorders, as well as technological advancements in drug discovery and advanced therapeutic modalities, is driving sustained growth in neuroscience drug discovery. This site move shows our continued investment in supporting drug discovery across debilitating neurodegenerative, psychiatric and brain injury disorders.”
Antti Nurmi, General Manager, Pharmacology
Located in Finland’s Lakeland region, Kuopio is a leading research hub that plays host to a large number of companies across several science parks and networks, as well as being home to the University of Eastern Finland and Savonia University of Applied Sciences. This expansion strengthens our role as a partner of choice for organizations driving breakthrough therapies.